NewLimit: Brian Armstrong's Game-Changing Longevity Venture Secures $130M in Series B Funding
Artificial Intelligence and Genomics-Focused Biotech Company Led by Coinbase CEO Secures $130 Million to Combat Aging
In the fascinating world of biotech, NewLimit, co-founded by Coinbase CEO Brian Armstrong, is raising the stakes in the quest for increased healthy lifespans. With a Series B funding round of $130 million led by Kleiner Perkins, this ambitious startup promises to transform aging through AI-driven cell reprogramming.
The new round attracted prominent investors such as Founders Fund, Dimension Capital, Elad Gil, Garry Tan of Y Combinator, and Stripe co-founder Patrick Collison. Fresh additions to the investor pool include former GitHub CEO Nat Friedman, Apple's former machine learning director Daniel Gross, and Khosla Ventures. This round brings the startup's total funding to over $170 million, following a $40 million Series A in 2023.
Reimagining Aging: A I-Powered Mission
Launched four years ago in collaboration with ex-GV partner Blake Byers and stem cell researcher Jacob Kimmel, NewLimit is set on therapies that enhance "healthy life expectancy." Rather than merely extending lifespan, NewLimit targets the epigenome, altering how cells behave without modifying their DNA. NewLimit's goal: to treat aging itself as the common denominator behind nearly every major human disease.
"As scientists uncover the mutable nature of aging, NewLimit stands tall at the forefront of this revolution," the company states.
A Billionaire's Quest For Biological Immortality
NewLimit's quest fits snugly within a growing trend of billionaire-backed longevity startups. Tech moguls, drawn to the tantalizing promise of reversing the age-old problem of aging, are pouring their resources into biotech.
Consider OpenAI CEO Sam Altman's support of Retro Biosciences, developing age-reversal drugs. Jeff Bezos, too, backs Altos Labs, who aim to restore cell health and resilience through cell rejuvenation. The Methuselah Foundation, named after the Bible's longest-living figure, strives to make 90 the new 50 by 2030, with high-profile donors like PayPal co-founder Peter Thiel and Ethereum's Vitalik Buterin.
NewLimit's approach combines large-scale genomics and AI-driven analysis. Its Discovery Engine conducts countless reprogramming experiments on human cells, while machine learning models help choose which cellular tweaks to pursue in the next cycle, streamlining experimentation.
Edited by Sebastian Sinclair
A Journey Through the Genetic Frontier: Subscribe to Our Newsletter
Enrichment Data: (15% Inclusion)
State-of-the-art Approach in Tackling Aging
- Epigenetic Reprogramming: NewLimit's focus on epigenetic reprogramming addresses aging from its roots, targeting cellular dysfunction rather than specific diseases[2][5].
- Prototype Medications: NewLimit recently identified three prototype medications that reprogram liver cells. Studies show that reprogrammed cells can metabolize fat and alcohol effectively, mirroring young cells' performance[1][4].
- Scalable Screening: By leveraging AI and single-cell sequencing, NewLimit conducts thousands of rapid therapy screenings, reducing costs and speeding up the process[5].
- NewLimit, co-founded by Brian Armstrong of Coinbase, aims to transform aging through epigenetic reprogramming, an approach in state-of-the-art aging research that focuses on cellular dysfunction rather than specific diseases.
- The ambitious startup, which has secured $130M in Series B funding, is venturing into the field of healthy life expectancy, targeting the epigenome to alter how cells behave without modifying their DNA.
- Notably, NewLimit is part of a growing trend of billionaire-backed longevity startups, including Retro Biosciences supported by OpenAI CEO Sam Altman and Altos Labs, which Jeff Bezos funds, both aiming to reverse aging through cell rejuvenation.
- In the realm of finance, Ethereum's Vitalik Buterin has shown support for the Methuselah Foundation, an organization that aims to make 90 the new 50 by 2030, a testament to the intersection of technology, finance, and health-and-wellness in this remarkable age.
- As the line between science, technology, finance, and health-and-wellness continues to blur, the exciting developments in the field of biological immortality, driven by pioneers like Brian Armstrong and his ventures, provide a clear glimpse into the promising future of fitness-and-exercise and a potential solution to some of humanity's most profound challenges, including aging.
